Collaborations & Alliances
Related Searches:
Filter by:
496 - 510 of 1104 results
February 15, 2011
Takeda’s Pharmaceutical Development Division has entered into strategic partnerships with Covance and Quintiles to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology.
Read More »
February 7, 2011
Pact covers characterization tools, services
Read More »
February 4, 2011
Merck and Galapagos NV have agreed to end their development alliances, and Galapagos has regained worldwide rights for all assets in the programs.
Read More »
January 28, 2011
PharmaNet Development Group, Inc. and Anapharm Europe, S.L., have ended their bioanalytical services joint venture as of December 22, 2010.
Read More »
January 26, 2011
Compound Focus unit to handle liquid chem library collection
Read More »
January 20, 2011
Evotec AG has entered into a collaboration with Takeda Cambridge Ltd., to identify small molecule modulators against GPCR and Protease targets to treat various CNS and Metabolic diseases.
Read More »
January 20, 2011
BioClinica, Inc. has established a strategic partnership with Symbiance Inc., a specialty CRO based in Princeton, NJ.
Read More »
January 13, 2011
Evotec AG has reached a milestone triggering a $2.6 million payment in its research alliance with Boehringer Ingelheim.
Read More »
January 12, 2011
DSM Pharmaceutical Products and Codexis, Inc. have signed an enzyme supply agreement granting DSM rights to use Codexis' custom biocatalysts and services.
Read More »
January 11, 2011
Eli Lilly and Co. and Boehringer Ingelheim entered a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.
Read More »
January 11, 2011
Galapagos NV has completed first-in-human trials with GLPG0555 in healthy volunteers in its arthritis alliance with GlaxoSmithKline.
Read More »
January 10, 2011
novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases.
Read More »
January 10, 2011
Bristol-Myers Squibb and Pharmasset have entered into a clinical collaboration agreement to evaluate BMS-790052, a NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset’s nucleotide polymerase inhibitor for the treatment of ch
Read More »
January 7, 2011
Emerald BioStructures has successfully achieved the second milestone in its collaboration with UCB on the structure-based discovery of small molecule modulators of undisclosed targets.
Read More »
496 - 510 of 1104 results
